Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations

Bing-bing Hao,Ke Ma,Jun-yu Xu,Ru-feng Fan,Wen-si Zhao,Xing-long Jia,Lin-hui Zhai,SangKyu Lee,Dong Xie,Min-jia Tan
DOI: https://doi.org/10.1038/s41401-024-01236-5
IF: 7.169
2024-02-22
Acta Pharmacologica Sinica
Abstract:Histone deacetylase inhibitors (HDACis) are important drugs for cancer therapy, but the indistinct resistant mechanisms of solid tumor therapy greatly limit their clinical application. In this study we conducted HDACi-perturbated proteomics and phosphoproteomics analyses in HDACi-sensitive and -resistant cell lines using a tandem mass tag (TMT)-based quantitative proteomic strategy. We found that the ribosome biogenesis proteins MRTO4, PES1, WDR74 and NOP16 vital to tumorigenesis might regulate the tumor sensitivity to HDACi. By integrating HDACi-perturbated protein signature with previously reported proteomics and drug sensitivity data, we predicted and validated a series of drug combination pairs potentially to enhance the sensitivity of HDACi in diverse solid tumor. Functional phosphoproteomic analysis further identified the kinase PDK1 and ROCK as potential HDACi-resistant signatures. Overall, this study reveals the potential HDACi-resistant signatures and may provide promising drug combination strategies to attenuate the resistance of solid tumor to HDACi.
pharmacology & pharmacy,chemistry, multidisciplinary
What problem does this paper attempt to address?